{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T08:18:06Z","timestamp":1774945086156,"version":"3.50.1"},"reference-count":36,"publisher":"PAGEPress Publications","issue":"1","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch Ital Urol Androl"],"abstract":"<jats:p>Introduction: Prostate cancer comprises biologically distinct subtypes. Ki67 reflects tumour proliferation, while prostate-specific antigen immunostaining (PSA-IHC) indicates differentiation, with low PSA-IHC suggesting dedifferentiation. The prognostic role of these markers in de novo metastatic hormone-sensitive prostate cancer (mHSPC) remains unclear.Aim: To evaluate the prognostic value of Ki67 and PSA-IHC, individually and combined, in de novo mHSPC, and explore their relevance across treatment modalities.Methods: We retrospectively analysed patients diagnosed with de novo mHSPC (2015-2020) who ultimately died from prostate cancer. Clinical data included age, ISUP grade, baseline and 7-month PSA, metastatic sites, and first-line treatment. Ki67 (MIB-1) and PSA-IHC were quantified as the percentage of positive nuclei and cytoplasmic staining, respectively. The 75th percentile defined high vs low expression. Endpoints were biochemical (bPFS), radiological (rPFS), castration-resistant progression-free survival (CRPC-FS), and overall survival (OS). Exploratory analyses were performed by treatment type: androgen receptor pathway inhibitors (ARPIs) or taxanes.Results: Sixty-seven patients were included (median age 77 years). Most had high-grade tumours (ISUP \u22653, 83.6%). High Ki67 (&gt;P75) correlated with shorter OS (10 vs 21 months, p=0.013). PSA-IHC &gt;P75 predicted longer bPFS (13 vs 9 months, p=0.027). Combined stratification identified distinct prognostic groups (p=0.034): PSA-IHC low\/Ki67 high defined a high-risk phenotype with poor outcomes, particularly among taxane-treated patients (p=0.006).Conclusions: Combined Ki67 and PSA-IHC assessment refines risk stratification in de novo mHSPC, identifying a high-risk PSA-IHC low\/Ki67 high subgroup with markedly worse prognosis. These findings warrant prospective validation.<\/jats:p>","DOI":"10.4081\/aiua.2026.14731","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T06:54:15Z","timestamp":1774940055000},"source":"Crossref","is-referenced-by-count":0,"title":["Prognostic value of Ki67 and PSA-immunostaining in &lt;i&gt;de novo&lt;\/i&gt; metastatic hormone-sensitive prostate cancer"],"prefix":"10.4081","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2079-8518","authenticated-orcid":false,"given":"Ana Marta","family":"Ferreira","sequence":"first","affiliation":[{"name":"Urology and Renal Transplantation Department, Centro Hospitalar e Universit\u00e1rio de Coimbra"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Jarimba","sequence":"additional","affiliation":[{"name":"Urology and Renal Transplantation Department, Centro Hospitalar e Universit\u00e1rio de Coimbra"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9","family":"Rego","sequence":"additional","affiliation":[{"name":"Urology and Renal Transplantation Department, Centro Hospitalar e Universit\u00e1rio de Coimbra"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00e3o","family":"Gama","sequence":"additional","affiliation":[{"name":"Pathology Department, Centro Hospitalar e Universit\u00e1rio de Coimbra"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Almeida","sequence":"additional","affiliation":[{"name":"Pathological Anatomy Department, ULS Coimbra"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Eliseu","sequence":"additional","affiliation":[{"name":"Urology and Renal Transplantation Department, Centro Hospitalar e Universit\u00e1rio de Coimbra"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasco","family":"Quaresma","sequence":"additional","affiliation":[{"name":"Urology and Renal Transplantation Department, Centro Hospitalar e Universit\u00e1rio de Coimbra"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Nunes","sequence":"additional","affiliation":[{"name":"Urology Department, ULS Coimbra"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vitor","family":"Sousa","sequence":"additional","affiliation":[{"name":"Pathology Department, Centro Hospitalar e Universit\u00e1rio de Coimbra"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnaldo","family":"Figueiredo","sequence":"additional","affiliation":[{"name":"Urology and Renal Transplantation Department, Centro Hospitalar e Universit\u00e1rio de Coimbra"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2549","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"219920","doi-asserted-by":"crossref","unstructured":"1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74:123-156.","DOI":"10.3322\/caac.21834"},{"key":"219921","unstructured":"2. Gillessen S, Attard G, Beer TM, et al. Management of patients with advanced prostate cancer: EAU-ESTRO-ESMO guidelines 2024. Eur Urol. 2024; 86:123-145."},{"key":"219922","doi-asserted-by":"crossref","unstructured":"3. James ND, de Bono JS, Spears MR, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017; 377:338-351.","DOI":"10.1056\/NEJMoa1702900"},{"key":"219923","doi-asserted-by":"crossref","unstructured":"4. Sweeney CJ, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015; 373:737-746.","DOI":"10.1056\/NEJMoa1503747"},{"key":"219924","doi-asserted-by":"crossref","unstructured":"5. Fizazi K, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017; 377:352-360.","DOI":"10.1056\/NEJMoa1704174"},{"key":"219925","doi-asserted-by":"crossref","unstructured":"6. Davis ID, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019; 381:121-131.","DOI":"10.1056\/NEJMoa1903835"},{"key":"219926","doi-asserted-by":"crossref","unstructured":"7. Chi KN, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019; 381:13-24.","DOI":"10.1056\/NEJMoa1903307"},{"key":"219927","doi-asserted-by":"crossref","unstructured":"8. Smith MR, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med. 2022; 386:1132-1142.","DOI":"10.1056\/NEJMoa2119115"},{"key":"219928","unstructured":"9. Attard G, et al. Metastatic hormone-sensitive prostate cancer: biology and treatment evolution. Nat Rev Clin Oncol. 2022; 19:695-709."},{"key":"219929","unstructured":"10. Chi KN, et al. Treatment advances in metastatic hormone-sensitive prostate cancer: optimizing patient selection and sequencing. Nat Rev Urol. 2023; 20:283-297."},{"key":"219930","unstructured":"11. Parker CC, et al. Individualizing systemic therapy for advanced prostate cancer: challenges and opportunities. Nat Rev Urol. 2024;21:145-160."},{"key":"219931","unstructured":"12. Zhao SG, et al. Molecular subtyping of prostate cancer using transcriptomic and proteomic signatures. Eur Urol. 2023; 83:265-278."},{"key":"219932","doi-asserted-by":"crossref","unstructured":"13. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000; 182:311-322.","DOI":"10.1002\/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9"},{"key":"219933","unstructured":"14. Cuzick J, Swanson GP, Fisher G, et al. Ki-67 is an independent predictor of prostate cancer death in routine clinical practice. Br J Cancer. 2012; 106:1026-1033."},{"key":"219934","doi-asserted-by":"crossref","unstructured":"15. Song Z, Zhou Q, Zhang JL, et al. Marker Ki67 as a prognostic biomarker for prostate cancer based on two cohorts. World J Clin Cases. 2024; 12:32-41.","DOI":"10.12998\/wjcc.v12.i1.32"},{"key":"219935","doi-asserted-by":"crossref","unstructured":"16. Pasquale M, et al. Ki67, but not neuroendocrine differentiation, predicts prognosis in primary prostate cancer patients. Radiol Oncol. 2016; 50:313-320.","DOI":"10.1515\/raon-2016-0033"},{"key":"219936","unstructured":"17. Blessin NC, et al. Automated Ki67 labeling index assessment in prostate cancer. J Pathol. 2023; 261:213-222."},{"key":"219937","unstructured":"18. Erbersdobler A, et al. Predictive value of prostate-specific antigen expression in tissue samples of prostate cancer. Hum Pathol. 2009;40:636-642."},{"key":"219938","unstructured":"19. Bonk S, et al. Prognostic and diagnostic role of PSA immunohistochemistry in prostate cancer. Oncol Rep. 2019; 42:2105-2113."},{"key":"219939","doi-asserted-by":"crossref","unstructured":"20. Spyratou V, et al. Ki67 and PSA expression are prognostic in metastatic hormone-na\u00efve prostate cancer. Scand J Urol. 2023;57:289-297.","DOI":"10.1080\/0284186X.2023.2254480"},{"key":"219940","unstructured":"21. Henshall SM, et al. Decreased expression of PSA and androgen receptor in advanced prostate cancer is associated with an aggressive phenotype. Mod Pathol. 2001; 14:1016-1024."},{"key":"219941","unstructured":"22. Pertega-Gomes N, et al. Loss of PSA expression combined with high proliferation index defines an aggressive molecular phenotype in prostate cancer. Mod Pathol. 2022;35:1183-1193."},{"key":"219942","unstructured":"23. Mori K, et al. Clinical outcomes of docetaxel versus ARPI as upfront therapy in mHSPC: impact of biological and pathological features. Eur Urol Oncol. 2024; 7:201-213."},{"key":"219943","unstructured":"24. Mateo J, et al. Biomarker-driven treatment selection in advanced prostate cancer: current status and future directions. Nat Rev Urol. 2024; 21:220-236."},{"key":"219944","unstructured":"25. Halabi S, Kelly WK, Ma H, et al. Meta-analysis evaluating the impact of Ki-67 on outcomes in advanced prostate cancer. J Clin Oncol. 2021; 39:1358-1368."},{"key":"219945","unstructured":"26. Epstein JI, Amin MB, Beltran H, et al. Contemporary histologic grading of prostate cancer: insights from pathology and molecular studies. Hum Pathol. 2018; 79:140-152."},{"key":"219946","unstructured":"27. Khalaf DJ, Sunderland K, Eigl BJ, et al. Ki67 expression and outcomes in metastatic hormone-sensitive and castration-resistant prostate cancer. Eur Urol. 2019; 75:976-983."},{"key":"219947","unstructured":"28. Montironi R, Cimadamore A, Scarpelli M, et al. Histopathology and molecular features of androgen receptor-independent prostate cancer. Pathology. 2020; 52:68-78."},{"key":"219948","doi-asserted-by":"crossref","unstructured":"29. Humphrey PA. Histological variants of prostatic carcinoma and their clinical significance. Histopathology. 2017; 70:59-74.","DOI":"10.1111\/j.1365-2559.2011.04039.x"},{"key":"219949","unstructured":"30. Beltran H, Hruszkewycz A, Scher HI, et al. The molecular landscape of neuroendocrine prostate cancer. Nat Med. 2019; 25:1608-1618."},{"key":"219950","unstructured":"31. Aparicio AM, Shen L, Tapia EL, et al. Combined tumor suppressor defects characterize clinically defined aggressive variant prostate cancers. J Clin Oncol. 2013;31:e2593-e2604."},{"key":"219951","unstructured":"32. Davies AH, Beltran H, Zoubeidi A. Cellular plasticity and the neuroendocrine phenotype in prostate cancer. Clin Cancer Res. 2019;25:6916-6924."},{"key":"219952","unstructured":"33. Tosoian JJ, Patel HD, Landis P, et al. Association of Ki-67 and PSA expression patterns with prostate cancer progression. BJU Int. 2021; 128:344-353."},{"key":"219953","unstructured":"34. Schweizer MT, Zhou XC, Wang H, et al. Molecular determinants of response to taxane chemotherapy in advanced prostate cancer. Clin Cancer Res. 2018; 24:4723-4731."},{"key":"219954","unstructured":"35. Abida W, Patnaik A, Campbell D, et al. Genomic correlates of clinical outcome in metastatic prostate cancer treated with taxanes. JAMA Oncol. 2023; 9:215-225."},{"key":"219955","unstructured":"36. Aggarwal R, Zhang T, Small EJ, et al. Molecular characterization of androgen receptor-independent prostate cancer. Nat Commun. 2021;12:1885."}],"container-title":["Archivio Italiano di Urologia e Andrologia"],"original-title":[],"link":[{"URL":"https:\/\/www.pagepressjournals.org\/aiua\/article\/download\/14731\/13910","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.pagepressjournals.org\/aiua\/article\/download\/14731\/13910","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T06:54:46Z","timestamp":1774940086000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.pagepressjournals.org\/aiua\/article\/view\/14731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,3,31]]}},"URL":"https:\/\/doi.org\/10.4081\/aiua.2026.14731","relation":{},"ISSN":["2282-4197","1124-3562"],"issn-type":[{"value":"2282-4197","type":"electronic"},{"value":"1124-3562","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,31]]}}}